Login
Companies $AUTL
$1.16 +$0.02 (1.75%) After hours
Autolus Therapeutics plc logo

Autolus Therapeutics plc

autolus.com

What Do They Do?

Sells AUCATZYL, an engineered T-cell treatment for adults with a type of blood cancer, and develops other T-cell treatments for cancer and autoimmune diseases.

How Do They Make Money?

Cardinal Health pays for AUCATZYL after delivery and acceptance at a treatment center. License agreements can bring upfront fees, milestone payments and royalties on licensed-product sales.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Product revenue, net
Sold outright

99%
License
Licensed
1.5%
FY2022: 97%

Who Are Their Customers?

Patients are the customers for AUCATZYL; Cardinal Health delivers it to authorized treatment centers. License revenue came primarily from Moderna.

Do Revenues Turn Into Profits?

No. It lost $287.5M in FY2025.

Operating income, FY2025
−359% of revenue
▼ −12% (Loss) vs FY2024 (−$241.4M, −2386%)
Net income, FY2025
−381% of revenue
▼ −30% (Loss) vs FY2024 (−$220.7M, −2180%)
Free cash flow, FY2025
−401% of revenue
▼ −33% (Loss) vs FY2024 (−$228.3M, −2256%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +95%
vs $21.2M in Q3 FY2025
Product revenue, net share of revenue vs 99.8% in Q3 FY2025
  • Nov 10, 2026 Raised its 2026 AUCATZYL outlook to at least the prior range's upper end The presentation said it expects to reach or exceed the prior $150 million upper end.
  • Aug 3, 2026 Raised full-year AUCATZYL revenue guidance The new range was $140 million to $150 million, up from $120 million to $135 million.
  • Apr 14, 2026 Changed its independent auditor It dismissed Ernst & Young LLP (UK) and engaged Ernst & Young LLP (US) for fiscal 2026.

Growing. Revenue grew 32.4x in 4 years, from $2.3M in FY2021 to $75.4M in FY2025, about 138% a year.

From development to sales The older report described obe-cel as investigational; the latest describes AUCATZYL as approved and sold in the United States, with a United Kingdom launch.

Broader disease focus Autoimmune disease has joined cancer as a development focus: the older report framed its T-cell programs around cancer, while the latest also discusses obe-cel development for lupus and multiple sclerosis.

Revenue over time
Product revenue, net License Grant
$100M$50M$0

Who Do They Compete With?

Competes with Amgen, Bristol Myers Squibb, Novartis, Janssen Biotech, Kite, Cabaletta, Kyverna, and Cartesian

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support